Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Haplo-HCT for Hematologic Malignancies
NCT02988466Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2017
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial in hematologic malignancy, sponsored by Masonic Cancer Center. Started Jan 2017; status: completed.
02
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02988466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988466.